The lawsuit claims that ADMA Biologics misled the market by failing to disclose an undisclosed related party transaction and utilizing channel stuffing practices to artificially inflate reported revenue. Plaintiffs allege the company lacked adequate internal controls, rendering public statements regarding business operations and financial prospects materially false or misleading. When these underlying details emerged, investors reportedly suffered significant financial losses.

Those interested in serving as lead plaintiff must petition the court by the August 10 deadline. While the firm encourages investors to retain experienced counsel, no class has been certified yet. Investors may choose their own representation, remain absent class members, or opt to do nothing at this stage. Participation in any potential future recovery does not strictly require acting as lead plaintiff. The Rosen Law Firm is handling the litigation on a contingency fee basis, meaning class members are not responsible for out-of-pocket costs.